Sangamo Stock Soars on Positive Hemophilia Treatment Trial

Sangamo Stock Soars on Positive Hemophilia Treatment Trial

Source: 
TheStreet.com
snippet: 

The company announced in a press release that its SB-525 developed with Pfizer was "generally well tolerated and demonstrated a dose-dependent increase in Factor VIII levels across the four dosage cohorts.